Brief: Kintor Pharmaceuticals Announced Successful Dosing Of The First Batch Of Patients For Acne Vulgaris Phase I/Ii Clinical Trial Of Pyrilutamide
16/04/2021 11:35
April 16 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMACEUTICALS ANNOUNCED SUCCESSFUL DOSING OF THE
FIRST
BATCH OF PATIENTS FOR ACNE VULGARIS PHASE I/II CLINICAL TRIAL OF
PYRILUTAMIDE
Source text for Eikon: ID:nPn12bjbka
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint